Clinical trials: sponsored by British Columbia Cancer Agency
Prostate Cancer
Optimizing Prostate Cancer Treatment in Men With Advanced Local Disease
Multi-modality therapy that includes a brachytherapy implant improves outcomes in locally advanced prostate cancer when compared to other radiation-based treatments, but is also associated with more adverse side effects.
- Trial name
- OPTiMAL (NCT03836196)
- Testing
- LDR Brachytherapy and External Beam Radiation Therapy
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- British Columbia Cancer Agency
Adjuvant Radiotherapy for Breast Cancer
Carbon-Fibre Accessory (CARA) for Supine Breast Positioning to Reduce Toxicity in Whole Breast Radiotherapy
This trial is designed to assess the efficacy of a novel carbon-fibre adjustable reusable accessory (CARA) for breast support to reduce skin toxicity and unwanted normal tissue dose in comparison to the current clinical standard…
- Trial name
- NCT04257396
- Testing
- Carbon-Fibre Adjustable Reuseable Accessory (CARA)
- Where
- 3 sites in Canada
- Volunteers
- 220 people
- Sponsor
- British Columbia Cancer Agency
Head and Neck Cancer
PATH Trial: Personalized Approaches in the Treatment of Head and Neck Cancer
1. To determine genomic markers of radioresistance by comparing patients with H\&N cancer who develop recurrence within twelve months of curative intent radiation and/or chemoradiotherapy to those without recurrence 2.
- Trial name
- PATH (NCT05373251)
- Testing
- Whole genomic DNA/RNA tumour sequencing
- Volunteers
- 500 people
- Sponsor
- British Columbia Cancer Agency
Ovarian Cancer, Ovarian Neoplasms
Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer
The purpose of this study is to use 18F-EF5 PET/CT scans to locate areas with low oxygen levels (hypoxia) in patients with recurrent and/or metastatic cancer.
- Trial name
- NCT01881451
- Testing
- 18F-EF5 PET/CT scan, Optional biopsy
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- British Columbia Cancer Agency
Cardiac Sarcoidosis
18F-FDG PET Imaging in Cardiac Sarcoidosis
This study has been designed to provide patients suspected of having cardiac sarcoidosis (CS) with a potentially diagnostic 18F FDG PET/CT.
- Trial name
- NCT01764191
- Testing
- 18F-Fluorodeoxyglucose (18F-FDG) PET/CT
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer, Prostatic Neoplasm
68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical
This is a preliminary evaluation of a radiotracer's biodistribution in human subjects. It is a prospective, single-centre, open-label, single group assignment interventional study.
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Prostatic Disease, Urogenital Neoplasms
- Trial name
- NCT04831307
- Testing
- [68Ga]Ga-HTK03149 PET/CT
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer
PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer
Purpose: To determine whether [18F]FES can predict clinical benefit (defined as complete response, partial response and stable disease ≥ 6 months) to fulvestrant (250 mg IM q 28 days) in post-menopausal women with recurrent or…
- Trial name
- NCT00816582
- Testing
- Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline, Diagnostic Imaging: 18F-FES PET/CT - Baseline, Diagnostic Imaging: 18F-FES PET/CT - 3 month follow-up
- Where
- 4 sites in Canada
- Volunteers
- 17 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer
A Randomized Trial of Letters From Family Physicians to Encourage Screening Mammography in Overdue Women
A randomized, double-blinded study conducted in British Columbia, Canada, where there is a publicly funded, organized screening program and screening mammography is recommended at 24-month intervals.
- Trial name
- NCT02660788
- Testing
- Standard Reminder Postcard, Family Physician Reminder Letter
- Where
- Canada
- Volunteers
- 5,498 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Living Well on Androgen Deprivation Therapy
Approximately half of men treated for prostate cancer will be offered hormone deprivation therapy during their cancer experience.
- Trial name
- NCT02108613
- Testing
- Exercise Sessions, Nutrition Education, Peer Support Volunteer
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
The purpose of this study is to assess whether patients who are likely to fail R-CHOP, as predicted by a mid-treatment PET scan, can have an improved outcome if switched to a standard salvage regimen R-ICE (rituximab, ifosfamide…
- Trial name
- LYTPET (NCT00324467)
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic Nodule
This study will investigate the feasibility of using technology of ultrasound guided HDR brachytherapy to focally increase dose to regions within the prostate that are heavily infiltrated with cancer.
- Trial name
- Dosepainting (NCT01605097)
- Testing
- HDR interstitial brachytherapy
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Cancer, Advanced Cancer
Real-world Clinical Effectiveness of Whole Genome and Transcriptome Analysis to Guide Advanced Cancer Care
This study aims to determine the clinical effectiveness of whole-genome and transcriptome analysis (WGTA) to guide advanced cancer care.
- Conditions
- Metastatic Cancer, Advanced Cancer, Cancers That Cannot be Treated With Curative Intent
- Trial name
- NCT04141397
- Testing
- Initiation of POG-related WGTA, Usual care
- Volunteers
- 1,200 people
- Sponsor
- British Columbia Cancer Agency
Neuroendocrine Tumors, Prostate Cancer
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
Quantitative parameters obtained with dynamic whole body imaging using positron emission tomography (PET) can provide additional and complementary information to standard PET.
- Conditions
- Neuroendocrine Tumors, Prostate Cancer, Prostatic Neoplasms, Carcinoid Tumor
- Trial name
- NCT04017104
- Testing
- 18F-FDG PET/CT, 68Ga-DOTATOC PET/CT, 18F-DCFPyL PET/CT
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Covid19
Detection of Covid-19 by Volatile Organic Compounds in Exhaled Breath
Our primary aim is to collect breath samples from COVID-19 positive patients at the time of diagnosis, during and after recovery using the same patient as his/her own control to identify VOCs specific to SARS-COV-2 viral…
- Trial name
- Covid-VOC (NCT04714333)
- Where
- 2 sites in Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Neuroendocrine Tumors
18F-AmBF3-TATE PET/CT for Imaging NET Patients
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called…
- Trial name
- NCT04207762
- Testing
- 18F-AmBF3-TATE PET/CT, Routine blood draw
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer, Interstitial Radiation
CT-validation of Ultrasound Based Planning for High Dose Rate (HDR) Prostate Brachytherapy Using Vitesse
High Dose Rate (HDR) temporary prostate brachytherapy offers a precise form of dose escalation for prostate cancer. Needles are placed, the position is confirmed and treatment is delivered.
- Conditions
- Prostate Cancer, Interstitial Radiation, High Dose Rate Brachytherapy, Ultrasound-based Planning Compared to CT-based Planning
- Trial name
- Vitesse (NCT01248741)
- Testing
- HDR prostate brachytherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer, Side Effect
CARA Treatment Pilot Study for Breast Positioning
CARA is a novel Carbon-fibre Adjustable and Re-usable Accessory for supine breast positioning during radiation therapy. CARA was developed at BC Cancer.
- Trial name
- NCT04543851
- Testing
- CARA - carbon fibre adjustable re-usable accessory for breast positioning
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
Circulating Tumor Cells
Cancer DNA Screening Pilot Study (CANDACE)
The investigators have developed an assay that can sensitively and specifically detect DNA mutations circulating in human plasma that may be indicators of the presence of a solid tumor.
- Trial name
- CANDACE (NCT02808884)
- Testing
- Circulating tumor DNA assay
- Where
- Canada
- Volunteers
- 1,514 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Metastatic Castration-Resistant Prostate Cancer
Sequencing Abiraterone and Enzalutamide in mCRPC
This study is being offered to patients who have castrate-resistant (also known as hormone-refractory) prostate cancer. The cancer has metastasized or spread outside the prostate area to other parts of the body.
- Trial name
- NCT02125357
- Testing
- Abiraterone acetate, Enzalutamide
- Where
- 7 sites in Canada
- Volunteers
- 202 people
- Sponsor
- British Columbia Cancer Agency
Brain Metastases
Whole Brain Radiotherapy Versus Volumetric Modulated Arc Therapy for Brain Metastases
Patients with brain metastases with expected life expectancy of 3-6 months are typically treated with radiotherapy to the whole brain giving a dose of 20 Gy over a 5 day period.
- Trial name
- Amadeus (NCT02220491)
- Testing
- Single-fraction radiotherapy, Whole-brain radiotherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency